Table 1 Clinical features of patients with dasatinib-induced nephrotic syndrome in previous case reports
From: Dasatinib-induced nephrotic syndrome in a patient with chronic myelogenous leukemia: a case report
Case | Author | Patient | Basal hematological disease | Duration of dasatinib administration | Urinary protein excretion | Serum creatinine (mg/dL) | Renal histology | Treatment | Prognosis |
|---|---|---|---|---|---|---|---|---|---|
1 | Wallace[4] | 63, F | CML | 3 months | 3.9 g/day | 0.79 | Focal foot process effacement | Switch to imatinib | remission |
2 | Hirano[5] | 64, F | Ph + ALL | 2 weeks | 3.9 g/day | 0.34 | NA | Dose reduction | remission |
3 | Ruebner[6] | 3, F | CML | 17 months | UP/Ucr = 17 g/gCr | 0.3 | Focal foot process effacement | Discontinue | remission |
4 | Lim YT[7] | 5, M | Ph + ALL | UP/Ucr = 15.24 g/gCr | NA | Diffuse foot process effacement | Discontinue | remission | |
5 | De Luca[8] | 45, F | CML | 6 months | 4.0 g/day | 0.9 | NA | Switch to imatinib | remission |
6 | Our case | 40, M | CML | 3 months | 5.7 g/day | 0.87 | Endothelial cell injury and foot process effacement | Switch to nilotinib | remission |